<!DOCTYPE html><html lang="en"><head><meta http-equiv="origin-trial" content="A/kargTFyk8MR5ueravczef/wIlTkbVk1qXQesp39nV+xNECPdLBVeYffxrM8TmZT6RArWGQVCJ0LRivD7glcAUAAACQeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZS5jb206NDQzIiwiZmVhdHVyZSI6IkRpc2FibGVUaGlyZFBhcnR5U3RvcmFnZVBhcnRpdGlvbmluZzIiLCJleHBpcnkiOjE3NDIzNDIzOTksImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9">
<script type="text/javascript" async="" src="https://www.google-analytics.com/analytics.js"></script><script type="text/javascript" async="" src="https://www.googletagmanager.com/gtag/js?id=UA-113590965-4&l=dataLayer&cx=c&gtm=45je4bc0v895705171za200"></script><script type="text/javascript" async="" charset="utf-8" src="https://www.gstatic.com/recaptcha/releases/-ZG7BC9TxCVEbzIO2m429usb/recaptcha__en.js" crossorigin="anonymous" integrity="sha384-gaZtYaI7oJHEOo1YO6VuoCE4iZ5fMV9mYHP0BHf+r2ttABnpWWCIkgI6ItNW4ZdO"></script><script async="" src="https://www.googletagmanager.com/gtag/js?id=G-REPSH58KSM"></script>
<script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-5KBPWNG"></script>
<meta charset="utf-8">
<meta http-equiv="content-language" content="en">
<meta name="google" content="notranslate">
<title>SCPH - Earnings call transcript Q3 2024 | scPharmaceuticals Inc.</title>
<meta property="og:title" content="SCPH - Earnings call transcript Q3 2024">
<meta property="og:description" content="2024 Q3 earnings call transcript for scPharmaceuticals Inc.">
<meta property="og:image" content="https://files.capedge.com/images/logo/1604950.png">
<meta property="og:url" content="https://capedge.com/transcript/1604950/2024Q3/SCPH">
<meta property="og:type" content="website">
<meta name="twitter:card" content="summary_large_image">
<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, shrink-to-fit=no">
<link rel="stylesheet" href="/css/style.css?v=20241113T075656">
<link rel="icon" sizes="32x32" type="image/png" href="/img/icon-200.png">
<link rel="apple-touch-icon" sizes="200x200" href="/img/icon-200.png">
<link rel="canonical" href="https://capedge.com/transcript/1604950/2024Q3/SCPH">
</head>
<body class="plan-free no-sidebar-wrap">
<a name="pageTop" id="pageTop"></a>
<div id="alert-container"></div>
<div class="d-lg-none" id="mobile-mode-canary"></div>
<div id="main-container">
<div id="above-footer">
<div class="container">
<div class="row align-items-center py-3 py-lg-2 d-print-none">
<div class="col-4 col-lg-3 order-1 pr-0">
<a href="/user/dashboard" id="logo-container"><img src="/img/capedge-logo-by-finsight.svg?v=20241113T075656" alt="CapEdge" width="174" height="37"></a>
</div>
<div class="col-12 col-lg order-3 order-lg-2 pt-3 pt-lg-0">
<form action="/search" method="get" id="mainSearchForm" spellcheck="false" autocomplete="off" role="search">
<div class="input-group">
<div class="tokenInput tokeninput-container tokeninput-empty flex-grow-1 form-control header-search">
<input id="searchInput" type="search" name="q" placeholder="Search by ticker, company or words in SEC filings" value="" tabindex="1" autocomplete="off" autocorrect="off" autocapitalize="off" style="width: 100%;">
<script class="tokeninput-data" type="application/json">
{
"resultDataProp":"suggestions",
"resultTextProp":"name",
"resultValueProp":"value",
"url":"/search/suggestions?profiles=true&q=$query&ctxType=company&ctxVal=1604950",
"values":[],
"type":"lookup",
"completionGroups" : {
"profiles" : { "heading" : "Filing Profile", "newOption" : false },
"searches" : { "heading" : "Search Across Filings, News and Transcripts", "newOption" : false }
},
"autoSuggestMode":true
}
</script>
</div>
<div id="searchLoading">Loading</div>
<div id="searchAdvanced" class="d-none"><a href="/help/search" tabindex="2">Advanced</a></div>
</div>
</form>
</div>
<div class="col-8 col-lg-3 order-2 order-lg-3">
<div class="d-flex justify-content-end align-items-center user-action-buttons">
<a href="https://help.capedge.com/release-notes/" target="_blank" class="mr-4 text-decoration-none header-help-link"><span class="d-xxl-none"><i class="fe fe-help-circle d-block"></i></span><span class="d-none d-xxl-block"><i class="fe fe-info"></i> What's new?</span></a>
<div class="btn-toolbar align-items-center" role="toolbar" id="favourites-toolbar">
<div class="btn-group" role="group">
<button type="button" id="btn-toggle-favourites" class="btn top-level active" data-toggle="tooltip" data-placement="bottom" title="" data-click-toggle="favourites-col" data-original-title="Toggle favorites"><i class="fe fe-star"></i></button>
<button type="button" id="btn-toggle-alerts" class="btn top-level" data-toggle="tooltip" data-placement="bottom" title="" data-click-toggle="alerts-col" data-original-title="Toggle alert feed"><i class="fe fe-bell"></i></button>
<button type="button" id="btn-toggle-notes" class="btn top-level" data-toggle="tooltip" data-placement="bottom" title="" data-click-toggle="notes-col" data-original-title="Toggle note list"><i class="fe fe-edit"></i></button>
<div class="btn-group" role="group">
<button class="btn top-level dropdown-toggle user-plan-free" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">TS</button>
<div class="dropdown-menu dropdown-menu-right">
<a class="dropdown-item" href="/user/edit">
<i class="dropdown-icon fe fe-user"></i>Edit profile
</a>
<a class="dropdown-item" href="/user/changepassword">
<i class="dropdown-icon fe fe-shield"></i>Change password
</a>
<a class="dropdown-item" href="/user/settings">
<i class="dropdown-icon fe fe-sliders"></i>Email settings
</a>
<a class="dropdown-item" href="/user/myaccount">
<i class="dropdown-icon fe fe-info"></i>Manage my account
</a>
<a class="dropdown-item" href="/user/support">
<i class="dropdown-icon fe fe-life-buoy"></i>Support
</a>
<div class="dropdown-divider"></div>
<div class="dropdown-item">
<form action="/user/logout" method="post">
<button type="submit" class="btn btn-sm btn-outline-primary w-100">Logout</button>
</form>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="row d-print-none">
<div class="col">
<ul class="nav nav-tabs align-items-center" id="primary-menu" data-test="menuMain">
<li class="nav-item" data-test="menuMainItem">
<a class="nav-link" href="/">Home</a>
</li>
<li class="nav-item" data-test="menuMainItem">
<a class="nav-link" href="/sector"><span class="d-none d-lg-inline">Sectors & Industries</span><span class="d-lg-none">Sectors</span></a>
</li>
<li class="nav-item separator"></li>
<li class="nav-item" data-test="menuMainItem">
<a class="nav-link" href="/earnings-calendar">Earnings</a>
</li>
<li class="nav-item" data-test="menuMainItem">
<a class="nav-link" href="/ipo-calendar">IPOs</a>
</li>
<li class="nav-item" data-test="menuMainItem">
<a class="nav-link" href="/transcript/by/companyId/all">Transcripts</a>
</li>
<li class="nav-item separator"></li>
<li class="nav-item" data-test="menuMainItem">
<a class="nav-link" href="/insider">Insider</a>
</li>
<li class="nav-item" data-test="menuMainItem">
<a class="nav-link" href="/institutional">Institutional</a>
</li>
<li class="nav-item right" data-test="menuMainItem">
<a class="nav-link" href="/user/dashboard">My Dashboard</a>
</li>
</ul>
</div>
</div>
<div class="row flex-nowrap pb-5" id="columns-row" data-open="1">
<div class="col order-2 sticky-scrolly user-feed-col mobile-toggle-only-one d-print-none " id="favourites-col">
<div class="">
<div class="btn-toolbar align-items-center w-100" role="toolbar" id="favourites-toolbar">
<div class="mr-auto toolbar-title" data-count="0">Favorites</div>
<div class="btn-group" role="group">
<button type="button" class="btn btn-sm" data-toggle="modal" data-target="#modalAddFavourite"><i class="fe fe-plus-circle"></i></button>
<button type="button" class="btn btn-sm d-md-none" data-click-toggle="favourites-col"><i class="fe fe-x"></i></button>
</div>
</div>
</div>
<div class="br">
<ul id="favourites-list" class="list-unstyled mb-0 w-100 empty-placeholder" data-count="0"></ul>
</div>
</div>
<div class="col order-3 sticky-scrolly user-feed-col mobile-toggle-only-one d-print-none collapsed" id="alerts-col">
<div class="">
<div class="btn-toolbar align-items-center w-100" role="toolbar" id="alerts-toolbar">
<div class="mr-auto toolbar-title">Alert feed</div>
<div class="btn-group" role="group">
<button type="button" class="btn btn-sm" data-toggle="modal" data-target="#modalAlertSettings" id="btn-alert-config"><i class="fe fe-settings"></i></button>
<button type="button" class="btn btn-sm d-md-none" data-click-toggle="alerts-col"><i class="fe fe-x"></i></button>
</div>
</div>
</div>
<div class="br">
<ul id="alerts-list" class="list-unstyled mb-0 block-list w-100 empty-placeholder">
</ul>
</div>
</div>
<div class="col order-4 sticky-scrolly user-feed-col mobile-toggle-only-one d-print-none collapsed" id="notes-col">
<div>
<div class="btn-toolbar align-items-center w-100" role="toolbar" id="notes-toolbar">
<div class="mr-auto toolbar-title" data-count="0">Notes</div>
<div class="btn-group" role="group">
<div>
<div id="add-note-recaptcha" class="g-recaptcha" data-sitekey="6Le1YlooAAAAAIpAmJQ9Vu8FsSGGsncij4tpVSol" data-callback="recaptchaAddNote" data-size="invisible"><div class="grecaptcha-badge" data-style="bottomright" style="width: 256px; height: 60px; display: block; transition: right 0.3s; position: fixed; bottom: 14px; right: -186px; box-shadow: gray 0px 0px 5px; border-radius: 2px; overflow: hidden;"><div class="grecaptcha-logo"><iframe title="reCAPTCHA" width="256" height="60" role="presentation" name="a-hexy6h4gms8f" frameborder="0" scrolling="no" sandbox="allow-forms allow-popups allow-same-origin allow-scripts allow-top-navigation allow-modals allow-popups-to-escape-sandbox allow-storage-access-by-user-activation" src="https://www.google.com/recaptcha/api2/anchor?ar=1&k=6Le1YlooAAAAAIpAmJQ9Vu8FsSGGsncij4tpVSol&co=aHR0cHM6Ly9jYXBlZGdlLmNvbTo0NDM.&hl=en&v=-ZG7BC9TxCVEbzIO2m429usb&size=invisible&cb=iufbaddct3w"></iframe></div><div class="grecaptcha-error"></div><textarea id="g-recaptcha-response" name="g-recaptcha-response" class="g-recaptcha-response" style="width: 250px; height: 40px; border: 1px solid rgb(193, 193, 193); margin: 10px 25px; padding: 0px; resize: none; display: none;"></textarea></div><iframe style="display: none;"></iframe></div>
<button type="button" class="btn btn-sm prevent-double-click" id="add-note-button"><i class="fe fe-plus-circle"></i></button>
</div>
<div class="dropdown" id="note-sort">
<button class="btn btn-sm" type="button" id="dropdownMenuButton" data-toggle="dropdown">
<i class="fe fe-settings"></i>
</button>
<div class="dropdown-menu dropdown-menu-right">
<h6 class="dropdown-header">Sort notes by</h6>
<button class="dropdown-item active" data-sort="created">Created</button>
<button class="dropdown-item" data-sort="updated">Updated</button>
<button class="dropdown-item" data-sort="title">Alphabetical</button>
</div>
</div>
<button type="button" class="btn btn-sm d-md-none" data-click-toggle="notes-col"><i class="fe fe-x"></i></button>
</div>
</div>
</div>
<div class="br">
<ul id="notes-list" class="list-unstyled mb-0 block-list w-100 empty-placeholder" data-limit="" data-count="0" data-num-displayed="" data-per-page="20"></ul>
<div id="note-list-end"></div>
</div>
</div>
<div class="col order-1 resp-container resp-sm resp-md" id="main-col" data-observe-resizes="true">
<div class="d-flex flex-column">
<div class="row mb-3 d-print-none secondary-menu-row order-2">
<div class="col">
<ul class="nav nav-tabs align-items-center px-4" id="secondary-menu" data-test="secondaryMenu">
<li class="nav-item " data-test="secondaryMenuItem">
<a class="nav-link" href="/company/1604950/SCPH">
<span class="tab-ticker">SCPH</span> Dashboard
</a>
</li>
<li class="nav-item " data-test="secondaryMenuItem">
<a class="nav-link" href="/company/1604950/SCPH/financials">
Financials
</a>
</li>
<li class="nav-item " data-test="secondaryMenuItem">
<a class="nav-link" href="/company/1604950/SCPH/filings">
Filings
</a>
</li>
<li class="nav-item disabled" data-test="secondaryMenuItem">
<div class="nav-link" href="/company/1604950/SCPH/holdings-history">
Holdings
</div>
</li>
<li class="nav-item " data-test="secondaryMenuItem">
<a class="nav-link" href="/transcript/by/companyId/1604950">
Transcripts
</a>
</li>
<li class="nav-item separator"></li>
<li class="nav-item " data-test="secondaryMenuItem">
<a class="nav-link" href="/company/1604950/SCPH/etfs">
ETFs
</a>
</li>
<li class="nav-item " data-test="secondaryMenuItem">
<a class="nav-link" href="/company/1604950/SCPH/insider-ownership-history">
Insider
</a>
</li>
<li class="nav-item " data-test="secondaryMenuItem">
<a class="nav-link" href="/company/1604950/SCPH/institutional-ownership-history">
Institutional
</a>
</li>
<li class="nav-item " data-test="secondaryMenuItem">
<a class="nav-link" href="/company/1604950/SCPH/short-interest">
Shorts
</a>
</li>
<li class="nav-item active " data-test="secondaryMenuItem">
<div class="nav-link" href="https://capedge.com/transcript/1604950/2024Q3/SCPH">
2024 Q3 Transcript
</div>
</li>
</ul>
</div>
</div>
<div class="row align-items-center py-6">
<div class="col">
<h1 class="page-title" data-test="pageTitle">
<span class="company-name">
scPharmaceuticals
(SCPH)
</span>
<span class="banner-crumb">13 Nov 24</span><span class="banner-crumb">2024 Q3 Earnings call transcript</span>
</h1>
<div class="my-1 text-muted-dark">
Company Profile
</div>
</div>
</div>
</div>
<div class="row" id="main-content-cols">
<div class="col order-1 sticky-scrolly mobile-toggle-only-one d-print-none default-sidebar-column" id="sidebar-col">
<div class="text-center mb-5 mobile-toggle-button-cont"><button type="button" class="btn btn-sm btn-outline-primary ml-auto" data-click-toggle="sidebar-col">< Back</button></div>
<div class="transcript-sidebar">
<div class="sidebar-annotations-container"><div class="annotator-editor card" style="display: none;">
<form>
<div class="card-header"><div class="card-title not-in-menu"><div class="d-block">Add <span class="annotation-type"></span></div></div></div>
<div class="card-body">
<ul class="annotator-listing"><li class="annotator-field form-group"><div class="quote" id="annotator-field-0" placeholder="Quote"></div></li><li class="annotator-field form-group"><textarea rows="3" class="form-control" id="annotator-field-1" placeholder="Comments…"></textarea></li><li class="annotator-field form-group"><label class="custom-switch pl-0"><input type="checkbox" class="custom-switch-input" id="annotator-field-2" placeholder="Visible to public"><span class="custom-switch-indicator"></span><span class="custom-switch-description">Visible to public</span></label></li><li class="annotator-field form-group"><input type="hidden" class="form-control" id="annotator-field-3" placeholder="In Reply To"></li></ul>
<div class="annotator-controls d-flex justify-content-between">
<button class="btn btn-primary annotator-save annotator-focus">Save <span class="annotation-type"></span></button>
<button class="btn btn-link annotator-cancel">Cancel</button>
</div>
</div>
</form>
</div><div class="annotator-viewer card" style="display: none;">
<div class="card-header">
<div class="card-title">Annotations</div>
<button type="button" class="btn btn-light ml-auto mobile-toggle-button-cont" id="close-mobile-annotations"><i class="fe fe-x"></i></button>
</div>
<ul class="card-body annotator-listing"></ul>
</div></div>
<div class="card">
<div class="card-header">
<div class="card-title">Share this transcript</div>
</div>
<div class="card-body">
<ul class="social-links list-inline mb-0">
<li class="list-inline-item m-0">
<a href="https://twitter.com/share?url=https%3A%2F%2Fcapedge.com%2Ftranscript%2F1604950%2F2024Q3%2FSCPH" target="_blank" rel="noreferrer noopener" data-toggle="tooltip" data-placement="top" title="" data-original-title="Share via Twitter"><i class="fe fe-twitter"></i></a>
</li>
<li class="list-inline-item m-0">
<a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fcapedge.com%2Ftranscript%2F1604950%2F2024Q3%2FSCPH&title=SCPH%20-%20Earnings%20call%20transcript%20Q3%202024%20%7C%20scPharmaceuticals%20Inc." target="_blank" rel="noreferrer noopener" data-toggle="tooltip" data-placement="top" title="" data-original-title="Share via LinkedIn"><i class="fe fe-linkedin"></i></a>
</li>
<li class="list-inline-item m-0">
<a href="mailto:?subject=SCPH%20-%20Earnings%20call%20transcript%20Q3%202024%20%7C%20scPharmaceuticals%20Inc.&body=https%3A%2F%2Fcapedge.com%2Ftranscript%2F1604950%2F2024Q3%2FSCPH" data-toggle="tooltip" data-placement="top" title="" data-original-title="Share via Email"><i class="fe fe-mail"></i></a>
</li>
<li class="list-inline-item m-0">
<a href="#" id="print-button" data-toggle="tooltip" data-placement="top" title="" data-original-title="Print"><i class="fe fe-printer"></i></a>
</li>
<li class="list-inline-item mr-0">
<a href="#" id="copy-link-button" data-toggle="tooltip" data-placement="top" title="" data-original-title="Copy URL to clipboard"><i class="fe fe-link"></i></a>
</li>
</ul>
</div>
</div>
<div class="card">
<div class="card-header">
<div class="card-title">Recent SCPH transcripts</div>
</div>
<ul class="container transcript-sidebar-list list-unstyled">
<li>
<a class="row item-row d-block transcript active" href="/transcript/1604950/2024Q3/SCPH">
<div class="d-flex">
<div class="title label-col">Earnings call transcript</div>
<div class="filing-type-col">
<div class="filing-period">2024 Q3</div>
</div>
<div class="date">13 Nov 24</div>
</div>
</a>
</li>
<li>
<a class="row item-row d-block transcript" href="/transcript/1604950/2024Q2/SCPH">
<div class="d-flex">
<div class="title label-col">Earnings call transcript</div>
<div class="filing-type-col">
<div class="filing-period">2024 Q2</div>
</div>
<div class="date">14 Aug 24</div>
</div>
</a>
</li>
<li>
<a class="row item-row d-block transcript" href="/transcript/1604950/2024Q1/SCPH">
<div class="d-flex">
<div class="title label-col">Earnings call transcript</div>
<div class="filing-type-col">
<div class="filing-period">2024 Q1</div>
</div>
<div class="date">14 May 24</div>
</div>
</a>
</li>
<li>
<a class="row item-row d-block transcript" href="/transcript/1604950/2023Q4/SCPH">
<div class="d-flex">
<div class="title label-col">Earnings call transcript</div>
<div class="filing-type-col">
<div class="filing-period">2023 Q4</div>
</div>
<div class="date">13 Mar 24</div>
</div>
</a>
</li>
<li>
<a class="row item-row d-block transcript" href="/transcript/1604950/2023Q3/SCPH">
<div class="d-flex">
<div class="title label-col">Earnings call transcript</div>
<div class="filing-type-col">
<div class="filing-period">2023 Q3</div>
</div>
<div class="date">8 Nov 23</div>
</div>
</a>
</li>
</ul>
</div>
<div class="card">
<div class="card-header">
<div class="card-title">Associated SCPH filings</div>
</div>
<ul class="card-body filing-sidebar-list list-unstyled mb-0">
<li class="clearfix ">
<a href="/filing/1604950/0000950170-24-126490/10Q-2024Q3" class="text-truncate filing-link">
<span class="filing-date">2024 Q3</span>
<span class="text-nowrap filing-type type-10Q type-financial">10-Q</span>
<span class="filing-description ">Quarterly report</span>
</a>
</li>
</ul>
</div>
</div>
</div>
<div class="col order-2">
<div id="toast-container"></div>
<button type="button" class="btn btn-sm btn-outline-primary mb-5 mx-auto d-block mobile-toggle-button-cont" data-click-toggle="sidebar-col"><i class="fe fe-more-vertical"></i> Transcript menu</button>
<div class="card transcript">
<div class="card-header">
<div class="card-title">Participants</div>
</div>
<div class="card-body">
<table class="participant-list">
<tbody><tr class="participant">
<td class="name">John Tucker</td>
<td class="role">executive</td>
</tr>
<tr class="participant">
<td class="name">Steve Parsons</td>
<td class="role">executive</td>
</tr>
<tr class="participant">
<td class="name">Rachael Nokes</td>
<td class="role">executive</td>
</tr>
<tr class="participant">
<td class="name">Stacy Ku</td>
<td class="role">analyst</td>
</tr>
<tr class="participant">
<td class="name">Douglas Tsao</td>
<td class="role">analyst</td>
</tr>
<tr class="participant">
<td class="name">Chase Knickerbocker</td>
<td class="role">analyst</td>
</tr>
</tbody></table>
</div>
</div>
<div class="card transcript">
<div class="card-header">
<div class="card-title">Call transcript</div>
</div>
<div class="card-body transcript-container">
<div class="speech">
<div class="participant-name">Operator</div>
<div class="content">
<p>Good afternoon and welcome to scPharmaceuticals Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, today's conference call is being recorded.
I would now like to turn the conference call over to Nick Colangelo, Investor Relations, to cover forward-looking statements. Nick, please go ahead.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Nick Colangelo</div>
<div class="content">
<p>Thank you, operator.</p>
<p>Before beginning today's earnings call, we would like to highlight the following forward-looking statements. All statements on this conference call other than historical facts are forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements regarding scPharmaceuticals' expected future financial results, management's expectations and plans for the business, the ongoing commercialization and marketing of FUROSCIX and other regulatory approvals of FUROSCIX. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements.
These forward-looking statements are not guarantees of the future performance. It may involve and are subject to certain risks and uncertainties and other crucial factors that may affect scPharmaceuticals' business, financial condition and other operating results. These include, but are not limited to, the risk factors and other qualifications contained in scPharmaceuticals' annual report on Form 10-K, quarterly reports on Form 10-Q and other reports filed by the company with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements.
Any forward-looking statements made in this conference call, including responses to your questions, are based on current expectations as of today, and scPharmaceuticals expressively disclaims any intent or obligation to update these forward-looking statements, except as required by law.
With that, I will now turn the call over to John Tucker, Chief Executive Officer of scPharmaceuticals. John, please go ahead.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Thank you, Nick, and thank you to everyone who has dialed in to this afternoon's call. I'll begin today's call by discussing the company's operational and business highlights for the third quarter of 2024 before handing the call to Steve Parsons, our Senior Vice President of Commercial, to provide a more thorough FUROSCIX commercial update.</p>
<p>We will then provide a detailed review of our financials from Rachael Nokes, scPharmaceuticals' Chief Financial Officer, before closing the call out with a question-and-answer session.
In the third quarter of 2024, we generated net revenue of $10 million. This represents an approximately 24% increase in net revenue from the second quarter of 2024.</p>
<p>While we were disappointed with where the third quarter ended, given the strong demand at the beginning of the quarter, we are pleased with the growth we have seen so far in the fourth quarter. We see this growth being driven by the sales force expansion, the indication expansion to include Class IV patients and continued growth in the IDN business. I will give a more comprehensive update on our longer-term growth initiatives momentarily.
FUROSCIX gross net discount was approximately 15.7%, just over the high end of the range of 10% to 15% that we guided to during our second quarter results. The increase in our GTN is largely due to lagging CMS reporting on coverage gap rebates and to a lesser degree on FUROSCIX sales to integrated delivery networks and hospital system pharmacies.</p>
<p>For the balance of 2024, we anticipate the GTN to stay in the 10% to 15% range. And in 2025, we anticipate the GTN discount to increase up to 35% by the end of the year, driven by the Medicare Part D redesign.
Please keep in mind, we feel the impact on the GTN to be more than offset by the lower patient co-pays due to the Medicare Part D redesign. We feel we are uniquely positioned to take advantage of the redesign and the lower patient out-of-pocket costs in 2025.</p>
<p>Looking towards our future growth opportunities for FUROSCIX, one of our long-term initiatives has been the FUROSCIX indication expansion to cover all heart failure patients, including Class IV patients that present more severe symptoms, more frequently and have the greatest limitation on physical activity. Despite consisting of roughly 10% of the overall chronic heart failure market, Class IV patients are responsible for over 30% of the hospitalization for heart failure and Class IV patients are more likely to benefit from FUROSCIX to manage their increased fluid events outside of the inpatient setting.
Ultimately, we are focused on getting patients back to their maintenance therapies without the costly hospitalization and delay in patients having symptom resolution. This is a message that resonates strongly with both physicians and their patients.</p>
<p>We are already filling prescriptions for Class IV patients and are seeing an uptick in the size of our prescriptions, reflecting larger script sizes in Class IV patients.</p>
<p>Another key objective we accomplished this quarter that relates to the ongoing franchise expansion in FUROSCIX was the acceptance of our sNDA filing by the FDA to expand the indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease or CKD. We believe FUROSCIX, if approved, has the potential to play an important role in the CKD market, again, being utilized by the patients who are comfortable with an at-home treatment option for their fluid buildup until their everyday oral loop diuretics treatment regime begins to work again.</p>
<p>While these oral loop diuretics are the current standard of care in fluid overload for CKD patients, they do have limitations, particularly around acute spikes in fluid levels given that these oral loop diuretics have less predictable bioavailability. It is crucial that CKD patients' fluid levels are well controlled as fluid overload in CKD is associated with both significantly increased mortality as well as a faster decline in renal function and dialysis initiation.
We've undertaken several steps to prepare for a potential launch of FUROSCIX in CKD. These initiatives include establishing a cross-functional team that has been field testing positioning, conducting exploratory market research, identifying key opinion leaders and calling on high-impact nephrologists who are already treating heart failure patients that also have CKD.</p>
<p>While we await our PDUFA date of March 6, 2025, we are undertaking every prelaunch activity to enable rapid commercial uptake should FUROSCIX receive approval for CKD.
The final growth initiative we were focused on executing over the course of the third quarter is our low-volume Autoinjector, which we announced positive top line results from a PK/PD bridging study in August.</p>
<p>Importantly, the auto Autoinjector demonstrated bioavailability of 107.3% and participants receiving the Autoinjector had similar urine output and urinary sodium and potassium excretion compared to IV furosemide.
The Autoinjector, if approved, has the potential to meaningfully reduce manufacturing costs compared to FUROSCIX current on-body infuser and offers a compelling treatment option for HCPs and patients.</p>
<p>We are continuing to work through our sNDA package and currently anticipate submitting to the FDA in January of 2025.</p>
<p>Before I hand the call to Steve Parsons for a more comprehensive overview of FUROSCIX launch metrics, I wanted to quickly highlight the transformative financing that we completed in early August that resulted in a net addition of roughly $75 million to scPharmaceuticals' balance sheet and bolsters our projected cash runway through expected profitability.</p>
<p>In addition to the $75 million that was immediately available, scPharmaceuticals has the ability to pull down an additional $50 million via both a debt and royalty stream facility that we put in place with Perceptive Advisors. In summary, we are pleased to have the validation and continued support from a great roster of both our new and existing equity investors.
I will now turn the call over to Steve Parsons, scPharmaceuticals' Senior Vice President of Commercial. Steve?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Steve Parsons</div>
<div class="content">
<p>Thank you, John. We remain encouraged by the continued progress achieved during the third quarter. From launch through September 30, 2024, approximately 3,100 unique health care providers have prescribed FUROSCIX, representing a 13% increase compared to the second quarter and is reflective of our efforts to expand the FUROSCIX prescriber base while still increasing utilization with existing repeat writers.</p>
<p>During the third quarter, we filled approximately 10,800 doses of FUROSCIX, up 16% from the previous quarter. Of note, the average number of doses per prescription has risen to 6.8 in the third quarter compared to an average of 6.3 doses in the second quarter. We anticipate this upward trend will continue driven by the expansion of the FUROSCIX indication to include Class IV and some health care providers writing larger prescriptions for patients.
Also, we have increased efforts over the past quarter to further penetrate advanced heart failure clinics.</p>
<p>Now that the NYHA class restrictions have been removed, we have seen that advanced heart failure patients typically receive a higher number of doses per prescription.
The new FUROSCIX Direct patient services hub continues to perform well following the transition. The hub allows for streamlined online prescription submissions and offers a real-time data dashboard that all prescribers value. The prescribers and their staff can now track key information, including the patient's prior authorization submission, approval status, the patient's co-pay amounts and the shipment date to the patient. This improved hub is intended to reduce friction from the prescribing process and we have received encouraging feedback from the health care providers thus far. They've highlighted the convenience and ease of access, which we believe will drive future increases in patient treatment volumes over the medium to long run.
Convenience and ease of access is also what we are hearing from the IDN hospital system customers who are seeking to bring FUROSCIX into their internal distribution systems, which connect to the e-prescribing system and captures FUROSCIX treatment data for all system specialists to see. Internal distribution can also support early discharge planning and meds to beds in addition to the normal home delivery service.
To conclude, we've expanded our number of territories to approximately 90 for the fourth quarter and we feel with reach and frequency on more customers during the highest treatment opportunity of the year that these factors will -- should have positive impact on our revenue.
With that, I would like to hand the call to Rachael Nokes, scPharmaceuticals' Chief Financial Officer.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Rachael Nokes</div>
<div class="content">
<p>Thank you, Steve, and good afternoon, everyone. Product revenues were $10 million for the third quarter of 2024 compared to $3.8 million for the third quarter of 2023. Cost of product revenues were $3.3 million for the third quarter of 2024, compared to $1.1 million for the third quarter of 2023. The increase in both product revenues and cost of product revenues for the quarter ended September 30, 2024 was due to an increase in demand of FUROSCIX further into commercial launch and related manufacturing costs.
Research and development expenses were $3.5 million for the third quarter of 2024 compared to $3.4 million for the third quarter of 2023. The increase in research and development expenses for the quarter ended September 30, 2024, was primarily due to an increase in clinical study costs, offset by a decrease in pharmaceutical development, quality, regulatory and employee-related costs.
Selling, general and administrative expenses were $21.3 million for the third quarter of 2024 compared to $14.1 million for the third quarter of 2023. The increase in selling, general and administrative expenses for the quarter ended September 30, 2024, was primarily due to costs associated with entering into the credit agreement and revenue purchase and sale agreement in August 2024, employee-related costs, commercial costs, patient support and professional service costs, offset by a decrease in taxes and insurance.
ScPharmaceuticals reported a net loss of $35.1 million for the third quarter of 2024 compared to $15.6 million for the third quarter of 2023. The increase in net loss for the third quarter of 2024 was primarily due to onetime charges related to the extinguishment of debt and accounting for the new financial instruments scPharmaceuticals entered into in August 2024.
ScPharmaceuticals' net loss for the third quarter of 2024 was $0.75 per share. The $0.75 per share was burdened by onetime charges of $0.47 per share. scPharmaceuticals ended the third quarter of 2024 with $91.5 million in cash and cash equivalents compared to $76 million in cash, cash equivalents and short-term investments as of December 31, 2023. The transformative debt and equity financing that was completed in August funds the company through expected profitability.</p>
<p>As of September 30, 2024, scPharmaceuticals' total shares outstanding was 50,040,134.
That concludes our financial update and I will now hand the call back to John for closing remarks before beginning our question-and-answer session.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Thank you, Rachael and thank you, Steve. This concludes our prepared remarks. At this point, we will open the call for questions. Operator?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Operator</div>
<div class="content">
<p>[Operator Instructions] Our first question comes from Roanna Ruiz with Leerink Partners.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Unknown Analyst</div>
<div class="content">
<p>This is [ Mesi ] on for Roanna Ruiz. We just have a couple of questions.</p>
<p>I think, first, curious as to what you think the doses per prescription could look like for FUROSCIX in CKD relative to heart failure.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Steve, do you want to answer that?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Steve Parsons</div>
<div class="content">
<p>Yes.</p>
<p>Our early research suggests it'll be similar. It won't be as high as Class IV heart failure patients, more like the Class II, Class III heart failure patients.</p>
<p>So in the 6 to 6.5 range.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Unknown Analyst</div>
<div class="content">
<p>Okay. And then with the potential Autoinjector, if approved, what do you think the rate of on-body diffuser versus Autoinjector could shake out to in the long term?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Yes.</p>
<p>So this is John. Yes, so we've modeled this based on some initial market research. We think at the end of the day 90-plus percent of this will be in the Autoinjector.</p>
<p>Now the transfer rate or the adoption rate will be driven by a number of things.
We don't think it will get to 100%. We know there are some patients who for years have struggled with fluid overload and going back and forth to the hospital, the IV clinic, found something that works and we'll stay with it. But we think the vast majority will move and new patients will adopt the Autoinjector.</p>
<p>So we think by the end of the conversion, it's 90% to 95% Autoinjector.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Unknown Analyst</div>
<div class="content">
<p>Okay.</p>
<p>Okay. And then a last one from us.</p>
<p>So what do you think about the holiday season? Is there any expected seasonality that we could see in Q4?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Yes, I'll turn that over to Steve.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Steve Parsons</div>
<div class="content">
<p>Yes. The fourth quarter of the year is the biggest opportunity of the year based on how many patients get admitted to the hospital, visit ERs, fluid overload is a big problem around holidays.</p>
<p>And so our model predicts that we'll have the most sales in the fourth quarter. That's where the most opportunity is for these patients.</p>
<p>So there is seasonality.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Yes.</p>
<p>And some doctors will actually preempt understanding that the patients are going to have too much salt, too much turkey, too much Chinese food, whatever and they will preempt by writing a script just in case that patient does get in trouble.</p>
<p>So we see an opportunity both in that pre-admission or even prophylactic therapy.
And as I said in my prepared remarks, we are seeing a good start to this quarter, and we haven't even really gotten close to the holidays yet.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Unknown Analyst</div>
<div class="content">
<p>Okay. Great. Well actually to follow up on that, when do you usually see that with this kind of stocking up, maybe physicians like prescribing for the holidays? Does that come in Q3? Or is that something that you expect to see more in the November, December period?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>It's a Q4 phenomenon.</p>
<p>So we'd expect to see it in November and December.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Operator</div>
<div class="content">
<p>Our next question comes from Stacy Ku with TD Cowen.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Stacy Ku</div>
<div class="content">
<p>We had a few.</p>
<p>So just first regarding Class IV patients.</p>
<p>As you exit the year, what percentage do you think will be Class IV? And long term, where do you think it could stabilize?
And then for CKD, still early days, but can you comment on how the initial nephrology detailing is going and what you're learning about the upcoming CKD launch?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Sure. Stacy, it's John. I'll take the Class IV.</p>
<p>So we think it's right now about 10%.</p>
<p>Now we didn't really launch it until September.</p>
<p>So it's early.</p>
<p>I think what we have seen though is an increase in the script size.</p>
<p>So there might be about 10% of our scripts as we're sitting here today. We think that will grow through the quarter and into next year. But I think as impactful to us is going to be the size of the scripts.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Steve Parsons</div>
<div class="content">
<p>Eight doses per prescription.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Yes. We're seeing about 8 doses per prescription on Class IV.</p>
<p>So we're enthused about how many scripts we're seeing for these patients, but also the size of the scripts. And as we've stated before, we think a lot of that could be palliative care where patients go to use an IV clinic to go in 3 times a week to get IV treatment, now they can do that at home as well as preventing using the hospital as an IV clinic.</p>
<p>As far as nephrology, the offices were called on and we just started this initiative a month, 1.5 months ago. But Steve, maybe you could talk a little bit about the reception we've had.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Steve Parsons</div>
<div class="content">
<p>Is the question about actual prescribing by nephrologists in heart failure? Or is it market research that your question was about?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Stacy Ku</div>
<div class="content">
<p>Just kind of curious what the reception is to -- right now, it's kind of concomitant heart failure and CKD patients. But I'm sure that's kind of giving the sales force and you all an idea of what the receptivity will be when you launch CKD. A little bit of both.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Steve Parsons</div>
<div class="content">
<p>Yes.</p>
<p>Okay. Well, it's pretty positive. We get a lot of inbound requests to go see nephrologists. Like they weren't on our original target plan for this year. They were going to be built in for next year. But we do get inbound requests for opening the account. They hear about it from cardiology.</p>
<p>So it's been pretty positive. They don't have access to IV in their offices, outpatient IV.</p>
<p>So they need a product like FUROSCIX and their adoption has been, I'd say, a little faster than cardiology in the offices that we've been to. They see the need, they see the overlap, cardiorenal and they prescribe.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Yes.</p>
<p>I think Steve made a really good point, Stacy, is that in heart failure, they'll sometimes have IV clinics at the heart failure clinic. Nephrologists really don't have access to that.</p>
<p>So you hear a lot of them using non-loop diuretics like metolazone out of sheer -- they have nothing else to use.</p>
<p>So we've been enthused about the reception and our market research in CKD.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Steve Parsons</div>
<div class="content">
<p>[ We just had ] American Society of Nephrology meeting a week ago and that was very positive, lots of leads.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Operator</div>
<div class="content">
<p>[Operator Instructions] Our next question comes from Doug Tsao with H.C. Wainwright.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Douglas Tsao</div>
<div class="content">
<p>John, I guess I'm just trying to understand a little bit around some of the dynamics that led to a little bit of a slower end of the quarter than you expected. Was it that your prescribers started to write less frequently as individuals? Or did your sort of the breadth of your script writing sort of diminished a little bit through the quarter?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Yes, Doug, we were disappointed with how the -- I guess, the second half of the quarter went. And it really was something we didn't fully -- you really can't handicap how your coverage gap rebates play in.</p>
<p>So the coverage gap rebates kind of hurt us in 2 places. One, in our GTN, which was -- we had given a range of 10% to 15%. It came in at 15.7%.</p>
<p>So we've been a little above the high end. Obviously, every point there costs you over $100,000 in revenue.</p>
<p>So that hurt us.
And then the flip side of the coverage gap rebate is when patients get in it, the ones that can afford to pay the higher co-pay, they pay it, it hurts you on your GTN because you're paying a 70% rebate on all of those patients. And that's what really drove the GTN. But on the flip side of that is when patients have high co-pays, we know they abandon it.</p>
<p>So we didn't -- we saw continued growth in scripts written. These patients that were in the coverage gap, a lot of them did not fill the script because of the co-pay. The good thing about that -- 2 good things about that, if there are any, the silver linings is in Q4, these patients have typically all gone through the gap and are now in catastrophic where their co-pays are lower and our responsibility is lower.</p>
<p>So it helps our GTN and helps the fill rate. And then again, next year, you don't have any coverage gap at all as you go to the redesign where patients out of pockets, if they smooth, cannot be more than $166.</p>
<p>So it's really a phenomenon on the coverage gap. It's always hard to anticipate early in a quarter what the gaps -- what the rebates are going to be and what that coverage gap co-pay is going to be. But that's what -- we didn't anticipate that level of coverage gap. We thought the patients had gotten through it in the second quarter, early in the third, but they clearly hadn't.</p>
<p>As we were looking at the co-pays coming in, they were higher than we had anticipated.
But the script demand was there, continued to grow. It's just that the fill rate in the first half of the quarter was much higher than it was in the second half of the quarter.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Operator</div>
<div class="content">
<p>Our next question comes from Chase Knickerbocker with Craig-Hallum.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Chase Knickerbocker</div>
<div class="content">
<p>Just first, and sorry if I missed it, jumping around on some calls here, what was the conversion rate in the third quarter? And I guess, what kind of improvement did you see kind of sequentially there?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Yes.</p>
<p>So, Steve, what was your...</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Steve Parsons</div>
<div class="content">
<p>We ended up at 53% fill rate of Rxs compared to about 48% in Q2 of Rxs. It was higher, as we said earlier in the quarter and moderated by the end of the quarter with the coverage gap patients, some of them declining 25% cost of the [ treatment ].</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>And keep in mind our fill rate still -- we have the dynamics of doctors putting product on layaway and also of just doing coverage determination.</p>
<p>So it's always noisy, but it did go up about 10% from Q2 to Q3. But clearly challenged a bit by coverage gap rebate patients in the quarter.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Chase Knickerbocker</div>
<div class="content">
<p>Got it.</p>
<p>And so doses written decelerated a little bit sequentially from a standpoint of growth. Was that largely this coverage gap kind of dynamic? Or is there any other kind of dynamics in the quarter that you'd call out?
And then, John, as we kind of are halfway through Q4 here, can you talk to kind of how that conversion rate looks so far in Q4?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Yes.</p>
<p>So to go back to Q3, yes, again, the coverage gap -- the thing about that, the script gets written and we did see growth in scripts from Q2 to Q3. We saw growth in filled units rise from Q2 to Q3, about 16%. That doesn't include the IDNs as well, which we added a number of IDNs, and that business continues to grow. In Q4 so far, Steve, on the fill rate, where do you...</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Steve Parsons</div>
<div class="content">
<p>54%, 55%.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>54%, 55%.</p>
<p>I think we're seeing a little tick up as patients get through the gap and into catastrophic. But we still have the phenomenon of coverage, co-pay determination and doctors writing layaway scripts.</p>
<p>So -- but we are seeing it trending up this quarter versus last. It trended up last quarter versus the quarter before.</p>
<p>So that's where we are.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Chase Knickerbocker</div>
<div class="content">
<p>Got it. And that kind of parlays into kind of my question kind of around next year. If we think about kind of the Part D redesign and what that can do again, for kind of improving conversion rates and generating hopefully increased demand as well, can you kind of talk a little bit to kind of any updated expectations as far as where you see that conversion rate going? And then last, guys, I'm sorry for all the questions, any return thus far on kind of the new reps that were hired in Q3? Happy with their progress thus far? I know it's early days, but any early green shoots there?</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Yes.</p>
<p>I think -- so let me answer the second question first. Yes, the new reps, we -- one thing we look at every week, every day is what percentage of the territories are contributing. And the new reps in the new territories have already started to contribute.
We didn't get them really out in the field until the beginning of October.</p>
<p>So there really was 0 impact of them in Q3. But we have seen -- and I think we said it usually takes 6 weeks or so to get them to make any contribution. They got to call on doctors a number of times to get them to write in new territories. But, yes, we've seen a contribution. That's why we're really excited about where we are because these reps are in the field. They're converting doctors now. The fill rate is ticking up. We think it will continue to tick up a bit this year.
And then next year you know what, I can tell you where our model is and we think the redesign, Chase, you and I have talked about it, is really, really beneficial for us. We're in a category where there's no competitor and patients will be able to smooth their co-pay.</p>
<p>So those coverage gap co-pays that are big, and we're talking big, over $1,000, $2,000, some of these co-pays, they're going to be at $166 a month. And these are heart failure patients, and that's for all of their meds.</p>
<p>So we're projecting 65% fill rate.</p>
<p>Now, the fill rate, that's great. But what that does also is you'll get more doctors prescribing as they understand more of their patients can afford the drug. And we're already out with the forms are out from the payers on how to sign patients up for the smoothing, all the plans -- there's is a CMS form, but the plans customize it a little bit.</p>
<p>We have all of the planned forms. They're in the hands of our specialty pharmacies and our hubs. And we're helping to sign them. We can't sign them up, but we can certainly provide them the form to get them signed up into the smoothing.</p>
<p>So we think 65%. Could that be higher? Yes, it could be. But I think the impact of that, obviously, is a big jump in your fill rate, but also a big jump in prescriptions being written.</p>
<p>So we look at the -- our tailwinds coming in for this quarter. It's the sales force expansion. It's a Class IV labeling.</p>
<p>For next year, even at January, you're going to have the benefit of the sales force expansion, you're going to have benefit of Class IV for the full quarter and you're going to have benefit of the redesign, which might be the most impactful of all of those things. And then in March, here comes our CKD indication in the beginning of March.</p>
<p>So we think it's setting up for a really interesting year for us next year.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Operator</div>
<div class="content">
<p>We have reached the end of our question-and-answer session. I would now like to turn the floor back over to John for closing comments. Please go ahead, sir.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">John Tucker</div>
<div class="content">
<p>Thank you very much and that concludes our call this afternoon.</p>
<p>As we have stated, we remain encouraged by the ongoing launch of FUROSCIX and are consistently receiving overwhelmingly positive feedback on how well FUROSCIX is performing and being accepted in the field.</p>
<p>We have a number of tailwinds at our back as we go through the fourth quarter and into 2025, including the expanded sales force, Class IV label expansion, the CKD indication in the first quarter of 2025 and the Medicare redesign that takes effect January 1, 2025. I look forward to a successful Q4 and providing our next update. Thank you very much.</p>
</div>
</div>
<div class="speech">
<div class="participant-name">Operator</div>
<div class="content">
<p>This concludes today's teleconference.</p>
<p>You may disconnect your lines at this time. Thank you for your participation.</p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<footer class="footer">
<div class="container">
<div class="row py-5">
<div class="col-12 col-lg-auto">
<a href="https://finsight.com" target="_blank" rel="noopener" class="no-icon mb-5 mb-lg-0">
<img src="/img/finsight.svg" alt="Finsight">
</a>
</div>
<div class="col-12 col-lg-auto ml-lg-auto">
<div class="row">
<div class="col">
<div class="link-title">Resources</div>
<ul class="list-unstyled">
<li><a href="https://help.capedge.com/" target="_blank">Knowledgebase</a></li>
<li>
<form action="/user/logout" method="post">
<button type="submit" class="btn btn-link">Logout</button>
</form>
</li>
</ul>
</div>
<div class="col">
<div class="link-title">Company</div>
<ul class="list-unstyled">
<li><a href="https://finsight.com/about" target="_blank" rel="noopener">About</a></li>
<li><a href="https://finsight.com/contact-us" target="_blank" rel="noopener">Contact</a></li>
<li><a href="https://finsight.com/our-solutions" target="_blank" rel="noopener">Solutions</a></li>
</ul>
</div>
<div class="col">
<div class="link-title">Products</div>
<ul class="list-unstyled">
<li><a href="https://dealroadshow.finsight.com/" target="_blank" rel="noopener">Deal Roadshow</a></li>
<li><a href="https://dealvdr.com/" target="_blank" rel="noopener">DealVDR</a></li>
<li><a href="https://evercall.co/" target="_blank" rel="noopener">Evercall</a></li>
<li><a href="https://finsight.com/" target="_blank" rel="noopener">Finsight.com</a></li>
</ul>
</div>
<div class="col">
<div class="link-title">CapEdge</div>
<ul class="list-unstyled">
<li><a href="/earnings-calendar">Earnings Calendar</a></li>
<li><a href="/transcript/by/companyId/all">Earnings Transcripts</a></li>
<li><a href="/search?q=">EDGAR Filing Screener</a></li>
<li><a href="/ipo-calendar">IPO Calendar</a></li>
</ul>
</div>
</div>
</div>
</div>
</div>
<div class="footer-bottom">
<div class="container">
<div class="row align-items-center">
<div class="col-12 col-lg-auto">
<ul class="list-inline mb-0">
<li class="list-inline-item"><a href="https://finsight.com/compliance" target="_blank" rel="noopener">Compliance</a></li>
<li class="list-inline-item"><a href="https://finsight.com/privacy-policy" target="_blank" rel="noopener">Privacy</a></li>
<li class="list-inline-item"><a href="https://finsight.com/security-policy" target="_blank" rel="noopener">Security</a></li>
<li class="list-inline-item"><a href="https://finsight.com/terms-of-use" target="_blank" rel="noopener">Terms</a></li>
</ul>
</div>
<div class="col footer-icons text-lg-right">
<a href="https://angel.co/company/finsight-group" target="_blank" rel="noopener" class="no-icon">
<img src="/img/angel.svg" alt="AngelList">
</a>
<a href="https://www.linkedin.com/company/finsight/" target="_blank" rel="noopener" class="no-icon">
<img src="/img/linkedin.svg" alt="LinkedIn">
</a>
</div>
</div>
</div>
</div>
</footer>
</div>
<div class="cookiesBanner_container cookiesBanner_container__visible">
<i class="cookiesBanner_close">
<svg width="16" height="16" viewBox="0 0 16 16" xmlns="http://www.w3.org/2000/svg">
<path d="M8.58719 7.3231C8.93627 7.67218 8.93627 8.23816 8.58719 8.58724C8.2381 8.93633 7.67213 8.93633 7.32304 8.58724L0.261813 1.52597C-0.0872709 1.17689 -0.0872709 0.61091 0.261813 0.261825C0.610896 -0.0872605 1.17687 -0.0872605 1.52596 0.261825L8.58719 7.3231Z"></path><path d="M1.52595 15.7382C1.17687 16.0873 0.610892 16.0873 0.261808 15.7382C-0.087275 15.3891 -0.0872754 14.8231 0.261808 14.474L7.32304 7.41277C7.67212 7.06368 8.2381 7.06368 8.58718 7.41276C8.93626 7.76185 8.93626 8.32783 8.58718 8.67691L1.52595 15.7382Z"></path><path d="M7.4128 8.6769C7.06372 8.32782 7.06372 7.76184 7.4128 7.41275C7.76189 7.06367 8.32786 7.06367 8.67695 7.41275L15.7382 14.474C16.0873 14.8231 16.0873 15.3891 15.7382 15.7382C15.3891 16.0873 14.8231 16.0873 14.474 15.7382L7.4128 8.6769Z"></path><path d="M14.474 0.261814C14.8231 -0.0872713 15.3891 -0.0872713 15.7382 0.261814C16.0873 0.610899 16.0873 1.17688 15.7382 1.52596L8.67695 8.58723C8.32787 8.93632 7.76189 8.93632 7.41281 8.58723C7.06373 8.23815 7.06373 7.67217 7.41281 7.32309L14.474 0.261814Z"></path>
</svg>
</i>
<div class="cookiesBanner_content">
<p class="cookiesBanner_text">
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our <a class="cookiesBanner_cookiesBannerLink__dvqOM" href="https://finsight.com/privacy-policy#cookiesPolicy" target="_blank">Cookie Policy</a> for more information.
</p>
<button type="button" class="cookiesBanner_btn btn btn-primary">I Agree</button>
</div>
</div>
<div class="modal fade" id="modalAddFavourite" tabindex="-1" role="dialog" aria-hidden="true">
<div class="modal-dialog" role="document">
<div class="modal-content">
<div class="modal-header">
<h3 class="modal-title">Add favorites</h3>
<button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
</div>
<div class="modal-body">
<ul class="nav nav-tabs" id="faveTabs" role="tablist">
<li class="nav-item">
<a class="nav-link active" id="manual-tab" data-toggle="tab" href="#manual" role="tab" aria-controls="manual" aria-selected="true">Choose</a>
</li>
<li class="nav-item">
<a class="nav-link" id="upload-tab" data-toggle="tab" href="#upload" role="tab" aria-controls="upload" aria-selected="false">Upload list</a>
</li>
</ul>
<div class="tab-content mt-3 pt-2" id="faveTabContent">
<div class="tab-pane fade show active" id="manual" role="tabpanel" aria-labelledby="manual-tab">
<form method="post" action="/user/batch-fave" spellcheck="false" autocomplete="off" id="batch-favorite-form">
<input type="hidden" name="referrer" value="">
<p>Type tickers, company names, or new folder names to organize your favorites.</p>
<div class="tokenInput tokeninput-container fake-input fake-input-lg">
<input type="text" placeholder="Ticker, company name, or new folder name…" name="favourites" autocomplete="off" autocorrect="off" autocapitalize="off" autofocus="on" size="42">
<script class="tokeninput-data" type="application/json">
{
"resultDataProp":"companies",
"resultTextProp":"name",
"resultValueProp":"companyId",
"url":"/search/company?needsXbrl=false&active=true&num=5&allowMultiple=true&q=$query",
"values":[],
"type":"lookup",
"completionGroups" : {
"companies" : { "heading" : "Companies", "newOption" : false, "singular" : "company" },
"folders" : { "heading" : "Folder", "newOption" : true, "singular" : "folder" }
}
}
</script>
</div>
<div class="d-flex mt-6 justify-content-between">
<button type="submit" class="btn btn-primary">Add favorites</button>
<button type="button" class="btn btn-link d-none d-md-inline-block" data-dismiss="modal">Cancel</button>
</div>
</form>
</div>
<div class="tab-pane fade" id="upload" role="tabpanel" aria-labelledby="upload-tab">
<div id="fave-upload-container">
<form method="post" action="/user/add-from-favorite-file">
<div class="not-uploaded">
<p>
Upload a CSV, TSV or Excel file of favorites to add (max 5 MB). We'll try to detect columns of tickers, company names, CIKs or CUSIPs. It doesn't
matter if the file has a header row or not, what order the columns are in, or if you include additional columns that are exported from another system.
</p>
<p>
If you want to organize your favorites into folders, then include a header row, with a column named <strong>Folder</strong> to
specify a folder for each favorite, e.g. (in this example, the name column is optional):
</p><pre> Name,Ticker,Folder
Apple Inc,AAPL,Watchlist
Tesla Inc,TSLA,Watchlist
Microsoft Inc,MSFT,Portfolio</pre>
<p></p>
<p>
If you want to upload a list of favorite searches, then include a header row, with a <strong>Name</strong> column for the search
terms, and a <strong>Type</strong> column with the value <em>search</em>, along with an optional <strong>Folder</strong> column e.g.
</p><pre> Type,Folder,Name
search,Future Tech,bitcoin OR cryptocurrency
search,Future Tech,S-1 drones
search,Green Energy,TSLA "renewable energy"</pre>
<p></p>
</div>
<div class="uploaded-only">
<table id="matched-upload-table" class="table table-sm">
<thead>
<tr>
<th></th>
<th colspan="2" class="uploaded-count">Uploaded</th>
<th colspan="2" class="matched-count">Matched</th>
<th class="folder-only">Folder</th>
</tr>
</thead>
<tbody></tbody>
</table>
<input type="hidden" name="uploadData" id="upload-data" value="">
<div class="mt-5 p-3 bg-blue-lightest">
<h6>Important:</h6>
<div class="form-check">
<input class="form-check-input" type="radio" name="actionExisting" id="actionExistingAdd" value="add" checked="">
<label class="form-check-label" for="actionExistingAdd">Add to existing favorites</label>
</div>
<div class="form-check">
<input class="form-check-input" type="radio" name="actionExisting" id="actionExistingReplace" value="replace">
<label class="form-check-label" for="actionExistingReplace">Remove existing favorites that are not in this list</label>
</div>
</div>
</div>
<div class="d-flex mt-6 justify-content-between">
<label class="btn btn-primary not-uploaded" for="upload-faves" id="upload-fave-button">
Upload favorites list…
<input type="file" id="upload-faves" class="d-none" name="files">
</label>
<button type="submit" class="btn btn-primary uploaded-only">Add selected favorites</button>
<button type="button" class="btn btn-link d-none d-md-inline-block" data-dismiss="modal">Cancel</button>
</div>
</form>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="modal fade" id="modalRenameFolder" tabindex="-1" role="dialog" aria-hidden="true">
<div class="modal-dialog" role="document">
<div class="modal-content">
<div class="modal-header">
<h3 class="modal-title">Rename folder</h3>
<button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
</div>
<form method="post" action="/user/rename-fave" spellcheck="false" autocomplete="off">
<div class="modal-body">
<input type="text" class="form-control" placeholder="Type new folder name…" name="documentSpecifier" autocomplete="off" autocorrect="off" autocapitalize="off" autofocus="on" pattern="[^<>]+">
<input type="hidden" name="documentId" value="">
</div>
<div class="modal-footer">
<button type="button" class="btn btn-link" data-dismiss="modal">Cancel</button>
<button type="submit" class="btn btn-primary">Rename</button>
</div>
</form>
</div>
</div>
</div>
<div class="modal fade" id="modalAlertSettings" tabindex="-1" role="dialog" aria-hidden="true">
<div class="modal-dialog" role="document">
<div class="modal-content">
<div class="modal-header">
<h3 class="modal-title">Alert feed settings</h3>
<button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
</div>
<form method="post" action="/user/settings" autocomplete="off" id="alert-settings-form" class="no-reset-on-close">
<div class="modal-body">
<p>Choose the information that appears in your CapEdge alert feed. You'll see alerts for information that matches your favorite companies.</p>
<div class="custom-controls-stacked mt-3">
<div class="form-group">
<label class="custom-switch pl-0">
<input type="checkbox" name="settings[alertTypes][]" value="ldb" class="custom-switch-input" checked="checked">
<span class="custom-switch-indicator"></span>
<span class="custom-switch-description">Filings</span>
</label>
<div class="pl-7 text-muted">New filings from SEC.</div>
</div>
<div class="form-group">
<label class="custom-switch pl-0">
<input type="checkbox" name="settings[alertTypes][]" value="news" class="custom-switch-input" checked="checked">
<span class="custom-switch-indicator"></span>
<span class="custom-switch-description">News</span>
</label>
<div class="pl-7 text-muted">Full news stories, breaking headlines, and press releases.</div>
</div>
<div class="form-group">
<label class="custom-switch pl-0">
<input type="checkbox" name="settings[alertTypes][]" value="social" class="custom-switch-input" checked="checked">
<span class="custom-switch-indicator"></span>
<span class="custom-switch-description">Social</span>
</label>
<div class="pl-7 text-muted">Message threads from Reddit.</div>
</div>
<div class="form-group">
<label class="custom-switch pl-0">
<input type="checkbox" name="settings[alertTypes][]" value="user" class="custom-switch-input" checked="checked">
<span class="custom-switch-indicator"></span>
<span class="custom-switch-description">Community content</span>
</label>
<div class="pl-7 text-muted">New community notes and annotations.</div>
</div>
</div>
</div>
<div class="modal-footer">
<button type="button" class="btn btn-link" data-dismiss="modal">Cancel</button>
<button type="submit" class="btn btn-primary">Update alerts feed settings</button>
</div>
</form>
</div>
</div>
</div>
<div class="modal fade" id="modalSendToNote" tabindex="-1" role="dialog" aria-hidden="true">
<div class="modal-dialog" role="document">
<div class="modal-content">
<div class="modal-header">
<h3 class="modal-title">Add to note</h3>
<button type="button" class="close" data-dismiss="modal" aria-label="Close"></button>
</div>
<form method="post" action="#" class="no-disable" spellcheck="false" autocomplete="off">
<div class="modal-body">
<p>The following content will be added to your chosen note:</p>
<div id="fragment-preview" class="my-3 text-muted"></div>
<p>Search or choose a recent note below:</p>
<div class="tokenInput tokeninput-container fake-input fake-input-lg">
<input type="text" placeholder="Search your note titles…" name="noteSearch" autocomplete="off" autocorrect="off" autocapitalize="off" tabindex="1" autofocus="on" size="25">
<script class="tokeninput-data" type="application/json">
{
"resultDataProp":"results",
"resultTextProp":"title",
"resultValueProp":"id",
"url":"/note/notesearch?limit=3&query=$query",
"type":"lookup",
"completionGroups" : {
"bestmatch" : { "heading" : "Best Match" },
"notes" : { "heading" : "Notes", "newOption" : true, "singular" : "note" }
}
}
</script>
</div>
<div id="send-recent-list"></div>
</div>
<div class="modal-footer">
<button type="button" class="btn btn-link" data-dismiss="modal" tabindex="2">Cancel</button>
</div>
</form>
</div>
</div>
</div>
<div class="dropdown-menu dropdown-menu-sm" id="user-feed-context-menu">
<a class="dropdown-item context-open" href="#">Open</a>
<a class="dropdown-item context-open" href="#" target="_blank">Open in new tab</a>
<div class="dropdown-divider"></div>
<a class="dropdown-item context-delete" href="#">Delete</a>
</div>
<div style="display:none" id="google-id" data-id="G-REPSH58KSM,UA-113590965-4"></div>
<div style="display:none" id="google-tag-id" data-id="GTM-5KBPWNG"></div>
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5KBPWNG" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script src="https://www.google.com/recaptcha/api.js" async="" defer=""></script>
<script type="application/json" id="user-data">{"id":"665437da02f04742ce51dd52","loggedIn":true,"settings":{"emailNewFilings":false,"emailSearches":true,"emailCommunityContent":true,"emailProductUpdates":true,"enableAnnotations":true,"enableReadCheckbox":false,"subscribedEmailFilingGroups":["financial","news","registration","proxy","other","ownership"],"subscribedEmailFilingTypes":[],"subscribedCommunityNotifications":["repliesToMine","newOnAnnotated"],"periodicEmailSchedule":"never","stockChartComparison":true,"stockChartPeriod":"1m","toggleFavouritescol":false,"toggleNotescol":true,"toggleAlertscol":true,"collapsedFolders":[],"collapsedCards":[],"annotationsPublic":false,"disableEmailNotes":false,"hideNextSteps":false,"alertTypes":["ldb","news","social","user"],"emailSearchesSchedule":"realtime","folderSettings":[]},"plan":"free"}</script>
<script type="application/json" id="init-data">{"annotationDocumentRoot":".transcript-container","annotationDocumentType":"transcript","annotationDocumentId":"SCPH_3408616","annotationCompanyId":1604950}</script>
<script src="/js/dist/initial.js?v=20241113T075656"></script>
<script src="/js/dist/build.js?v=20241113T075656" defer=""></script>
<script src="/js/dist/annotator.js?v=20241113T075656" defer=""></script>
<script async="" src="/js/dist/annotator-frame.js"></script><div class="annotator-adder" style="display: none;"><button type="button" class="sendTo">Add to note</button><button type="button" class="create">Annotate</button></div></body></html>